Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 3/20 | 0.33 |
| ▸ | CDK8 | P49336 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064707 | 0.85 | KDM5A (0.33) | CCNCCDK8KDM5A | |
| SCHEMBL20012745 | 0.78 | KDM5A (0.31) | CCNCCDK8KDM5A | |
| SCHEMBL12039663 | 0.72 | CPA1 (0.41) | CPA1CPB2KDM5A | |
| SCHEMBL20012481 | 0.70 | OPRM1 (0.32) | — | |
| SCHEMBL23115030 | 0.69 | CPA1 (0.31) | CPA1CPB2 | |
| SCHEMBL20907767 | 0.69 | CPA1 (0.31) | CPA1CPB2 | |
| SCHEMBL18081255 | 0.68 | CCNC (0.47) | CCNCCDK8 | |
| SCHEMBL17297334 | 0.68 | CCNC (0.47) | CCNCCDK8 | |
| SCHEMBL18081259 | 0.68 | CCNC (0.47) | CCNCCDK8 | |
| SCHEMBL11839667 | 0.68 | CCNC (0.39) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | CPA1 4227/4885CPB2 3251/4885CCNC 3381/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CPA1 4227/4885CPB2 3251/4885CCNC 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.